Some patients have a favorable response to osteoporosis treatment yet remain at very high risk for fracture. Is response to treatment good enough or should we do more?

FRAX is validated for use in untreated patients but some studies suggest it predicts fractures in treated patients as well. Should we use it in treated patients and if so, how do we do it?

As a follow-up to last year's successful presentation on the same topic, this webinar will tackle the above questions among other familiar challenges. A panel of osteoporosis experts will discuss common scenarios where clinical practice guidelines and randomized placebo-controlled clinical trials may not provide clear answers to clinical questions. They will provide insights on applying their clinical skills with the best available medical evidence to care for these patients.

As a result of this webinar participants will be able to:

• Identify treatment decisions in high risk patients considering drug mechanism of action as well as clinical trial data.
• Determine if response to therapy is an acceptable clinical endpoint in patients at very high risk for fracture.
• Discuss management of high risk patients after atypical femur fractures.
• Individualize patient care decisions.

Jointly Provided by Creighton University Health Sciences Continuing Education

Supported by an educational donation provided by Amgen

Length: 60 minutes